Every Form 4 that Kymera Therapeutics, Inc. (KYMR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KYMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KYMR filings page.
Kymera Therapeutics, Inc. (KYMR) reported that Chief Legal Officer Brian Adams sold a total of 6,371 shares of common stock on September 4, 2026. The company states these sales were required to cover tax withholding obligations upon vesting of restricted stock units and occurred automatically, not at his discretion. No Rule 10b5-1 trading plan is reported.
Rooney Terence reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics, Inc. reported that Chief Medical Officer Terence Rooney received equity awards consisting of 76,000 stock options to buy common stock at $110.05 per share, expiring July 26, 2036, plus 38,000 restricted stock units. The RSUs vest in four equal annual installments following July 27, 2026, and the options vest 25% on July 27, 2027 with the remainder in 36 equal monthly installments, in each case subject to his continued employment.
Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported an option exercise and related stock sale. He exercised stock options to acquire 50,000 shares of Common Stock at an exercise price of $2.08 per share, then sold 50,000 Common shares at an average price of $119.00 per share.
Following these transactions, he directly owned 666,568 Common shares. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and the options involved were fully vested and exercisable.
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of stock option exercises and share sales in Kymera Therapeutics, Inc. common stock. On June 30, 2026, he exercised options to acquire 61,378 shares at an exercise price of $5.33 per share and then sold 77,109 shares in open-market transactions. The sales occurred in multiple trades at weighted average prices within ranges from $110.37 to $118.09 per share, as detailed in the price footnotes. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated March 23, 2026, indicating they were scheduled in advance. Following the transactions, Jacobs directly holds 244,883 shares of Kymera common stock.
Kymera Therapeutics Chief Business Officer Noah Goodman sold 3,389 shares of common stock in an open-market transaction at $114.29 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the sale, Goodman directly holds 47,179.438 shares, which includes 373 shares acquired through Kymera’s employee stock purchase plan.
Kymera Therapeutics CEO Nello Mainolfi reported a mix of option exercises and share sales in the company’s stock. On July 1, 2026, he exercised stock options for 80,000 shares of common stock at an exercise price of $2.08 per share, converting a derivative position into regular shares.
That same day, he sold 80,000 shares of common stock in five open-market transactions at weighted average prices ranging from about $112.28 to $116.63 per share. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan dated March 24, 2026, and notes that he continues to hold a substantial direct equity stake in Kymera.
Kymera Therapeutics director-related entities reported an amended open-market sale of Kymera common stock. Entities associated with Bruce Booth, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a total of 76,650 shares of Kymera Therapeutics, Inc. on June 29, 2026.
The trades were executed as open-market sales at weighted average prices within ranges from about $105.02 to $111.63 per share under a Rule 10b5-1 trading plan adopted on December 11, 2025. The filing is an amendment that corrects previously misreported numbers of shares disposed and owned following the transactions. Booth reports these holdings indirectly through the Atlas funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics director Bruce Booth reported indirect open-market sales of a total of 31,283 shares of Kymera common stock on June 29, 2026. The trades, executed at weighted-average prices between about $108 and $111 per share, were made under a pre-arranged Rule 10b5-1 trading plan by Atlas Venture funds that hold the shares, for which Booth disclaims beneficial ownership beyond any pecuniary interest.
Kymera Therapeutics, Inc. director Bruce Booth reported that investment entities associated with him, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a combined 513,245 shares of Kymera common stock in open-market transactions.
The sales occurred on June 26 and June 29, 2026 at weighted-average prices such as $118.66 and $105.78 per share, executed under a pre-established Rule 10b5-1 trading plan. The filing shows that these entities continue to hold large indirect positions, including reported post-transaction holdings of 466,077 and 2,603,048 shares.
Funds affiliated with BVF Partners reported significant stock sales in Kymera Therapeutics, Inc. common shares. On 2026-06-26, Section 13(d) group members filed a joint Form 4 showing open-market sales totaling 1,630,658 shares of Kymera common stock at $106.50 per share, split between direct and indirect holdings.
The filing also lists a series of vested and time-based stock options, with exercise prices ranging from $14.18 to $99.87 per share and expirations from 2030 to 2036, held indirectly through BVF-managed entities. In addition, the group retains several pre-funded warrants exercisable at $0.0001 per share that, according to the disclosure, are exercisable at any time and do not expire. Collectively, these derivatives indicate that BVF-affiliated vehicles remain substantial economic holders of Kymera beyond the reported common share sales.
Kymera Therapeutics, Inc. reported that entities associated with director Bruce Booth sold a total of 285,684 shares of Kymera common stock on June 25 in open-market transactions. The sales were executed by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and are reported as indirect interests, with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. director-affiliated funds reported sizable open-market sales of common stock. Venture funds associated with director Bruce Booth sold a combined 398,765 shares of Kymera common stock in 30 open-market transactions from June 23–25, 2026. The trades were executed through Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Reported sale prices were weighted averages, with individual trades occurring in ranges from about $99.95 to $119.0789 per share. Booth is a member of the general partners of these funds and disclaims Section 16 beneficial ownership except for any pecuniary interest.
Kymera Therapeutics, Inc. had a group of BVF-affiliated reporting persons update their ownership in its securities. The only new transaction was an indirect grant of 6,068 stock options linked to common stock at an exercise price of $99.8700 per share.
These options expire on June 23, 2036 and vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. The filing also restates existing holdings in common shares, previously granted stock options, and pre-funded warrants that are exercisable at $0.0001 per share and do not expire.
Kymera Therapeutics, Inc. director Bruce Booth received a grant of stock options covering 6,068 shares of common stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
These options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. Following this grant, Booth holds options for 6,068 shares. According to the disclosure, proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Booth disclaims ownership except to the extent of any pecuniary interest.
Kymera Therapeutics director Gorjan Hrustanovic reported receiving a grant of stock options covering 6,068 shares of Common Stock. The options carry an exercise price of $99.87 per share and expire on June 23, 2036.
The underlying 6,068 shares vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting. According to the disclosure, Hrustanovic is a member of BVF Partners L.P. and is obligated to transfer any economic benefit from the sale of shares issued upon exercise of these grants to BVF, and he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kymera Therapeutics Chief Business Officer Noah Goodman reported an exercise-and-sell transaction in company stock. He exercised stock options for 5,000 shares of Common Stock at an exercise price of $21.05 per share, then sold 5,000 shares in two open-market sales at prices of $119.00 and $109.00 per share.
After these transactions, he directly holds 50,195.438 shares of Common Stock and 90,000 stock options. The filing notes that the sales were effected under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.
Kymera Therapeutics director Jeffrey W. Albers received a new stock option grant covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related award rather than an open-market share purchase or sale.
Kymera Therapeutics director Elena Ridloff reported a new equity award. She received a stock option covering 6,068 shares of common stock at an exercise price of 99.87 per share, expiring on June 23, 2036. The option vests in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale, and results in Ridloff holding 6,068 derivative securities directly.
Kymera Therapeutics director Sandor Victor received a new stock option grant. On June 24, 2026, he was awarded options covering 6,068 shares of Kymera common stock with an exercise price of $99.87 per share. These options give him the right to buy shares at that price in the future.
The options expire on June 23, 2036. According to the vesting terms, all 6,068 underlying shares will vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual meeting of stockholders. After this grant, Victor holds options for 6,068 shares directly.
Kymera Therapeutics director Pamela Esposito received a new stock option grant. She was granted options covering 6,068 shares of Kymera Therapeutics common stock at an exercise price of $99.87 per share, with no cash paid for the grant itself.
The option vests in full on the earlier of June 24, 2027 or the date of the company’s next annual stockholder meeting, aligning vesting with her continued board service. Following this award, Esposito holds derivative securities representing 6,068 underlying common shares according to this filing.
Kymera Therapeutics director John Maraganore received a grant of stock options covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. All 6,068 options were reported as directly owned after the transaction. According to the footnote, these options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Kymera Therapeutics reported a routine equity compensation grant linked to Baker Bros.-affiliated funds. A single award of 6,068 non-qualified stock options exercisable into Kymera common stock was granted in connection with Felix J. Baker’s service on the board. The options have a strike price of $99.87 per share, vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, and expire on June 23, 2036. Under Baker Bros. Advisors policies, Felix Baker has no direct pecuniary interest; the economic benefit and voting and dispositive power reside with the Baker Brothers Life Sciences and 667 funds and their investment adviser.
Kymera Therapeutics, Inc. reported insider-related open-market sales of its common stock by Atlas Venture funds associated with director Bruce Booth. On June 22, 2026, entities reported aggregate sales of 31,798 shares at weighted average prices around $103–$104 per share under a pre-established Rule 10b5-1 trading plan.
The shares are held directly by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with Booth disclaiming Section 16 beneficial ownership except for any pecuniary interest. After these transactions, related entities reported holdings of 613,762 and 3,472,340 Kymera shares, indicating they continue to hold substantial positions.
Kymera Therapeutics director‑associated entities reported sizeable June stock sales alongside an option exercise. Across June 17–22, entities linked to Bruce Booth sold a net 478,198 shares of Kymera common stock in open‑market transactions at prices generally around the low‑ to low‑$100 range.
Most shares are held directly by Atlas Venture Fund X and Atlas Venture Opportunity Fund I; Booth is a member of their general partners and disclaims Section 16 beneficial ownership beyond any pecuniary interest. On June 17, he exercised stock options for 11,741 shares at $20.00 per share and sold all those shares at a weighted‑average price of $89.98, leaving no direct common‑stock holdings but 28,127 fully vested options outstanding that expire on August 19, 2030. Several sales were executed under Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options for 2,500 shares of common stock at $21.05 per share and on the same day sold 2,500 shares in an open-market transaction at $99.00 per share. Following these transactions, he directly holds 50,195.438 shares of common stock. The trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 12,653 shares of common stock at an exercise price of $2.08 per share. The corresponding stock option for 12,653 shares was fully exercised and now shows zero derivative shares remaining. Following this transaction, Jacobs holds 260,241 shares of Kymera Therapeutics common stock directly, with no related sale or tax-withholding disposition reported in this filing.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported selling 17,184 shares of common stock in open-market transactions. The sales occurred on May 26–27, 2026 at weighted-average prices within ranges from about $77.99 to $82.15 per share. A footnote explains that the shares were required to be sold to cover tax withholding obligations tied to vesting restricted stock units and that these sales were automatic, not at his discretion. The transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 44,018 Kymera shares.
Kymera Therapeutics director Pamela Esposito exercised stock options to acquire 1,000 shares of Common Stock at an exercise price of $31.20 per share. After the transaction, she held 1,000 Common shares directly and 9,000 stock options with a $31.20 exercise price expiring on June 18, 2034. The filing notes that the shares underlying this option grant are fully vested and exercisable.
Kymera Therapeutics, Inc. Chief Financial Officer Bruce N. Jacobs exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.08 per share. Following this transaction, he directly holds 247,588 shares of common stock and 12,653 stock options that remain outstanding and expire on August 28, 2029.
Kymera Therapeutics director Elena Ridloff reported an exercise-and-sale transaction in company stock. She exercised stock options for 3,000 shares of common stock at $31.20 per share and sold 3,000 shares in an open-market transaction at $87.00 per share. Following these trades, her direct common stock holdings reported in this filing are zero, while 13,000 stock options remain outstanding and exercisable, expiring on June 17, 2034. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 11, 2025, indicating they were scheduled in advance.
Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock. On April 29, 2026, he exercised stock options to acquire 30,000 shares at $2.08 per share and then sold 30,000 shares of common stock in open-market trades.
The sales were split into blocks of 936, 12,059, and 17,005 shares at weighted average prices of about $82.45, $81.70, and $80.74. According to the filing, these trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Mainolfi directly held 666,195 shares of Kymera common stock.
Kymera Therapeutics director Bruce Booth reported option exercises and related share sales in Kymera Therapeutics, Inc. common stock. On April 22, 2026 he exercised options for 259 shares at $20.00 per share and 5,641 shares at $14.18 per share, then sold 5,900 shares in open‑market transactions at a weighted average price of about $89.96 per share, leaving no directly owned shares.
Entities associated with Atlas Venture made additional small sales of 12 and 88 shares at $90.08 per share. After these trades, Atlas Venture Fund X, L.P. held 674,944 shares and Atlas Venture Opportunity Fund I, L.P. held 3,899,829 shares, with Booth disclaiming Section 16 beneficial ownership except to any pecuniary interest. The filing notes these sales were made under pre‑arranged Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale. On April 22, 2026, he exercised stock options for a total of 300 shares of common stock at exercise prices of $43.50 and $30.17 per share, then made an open-market sale of 300 shares at $90.00 per share. After these transactions, he directly held 61,202 shares of Kymera common stock. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating they were scheduled in advance rather than timed discretionarily.
Kymera Therapeutics, Inc. Chief Business Officer Noah Goodman reported an open-market sale of company stock. On April 14, 2026, he sold 1,347 shares of Kymera common stock at $90.00 per share. After this transaction, Goodman directly holds 50,195.438 shares of common stock.
The filing notes that these transactions were made under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported option exercises and related share sales. On April 14–15, 2026, he exercised stock options to acquire a total of 6,551 shares of common stock at exercise prices of $30.17 and $43.50 per share.
On the same dates, he sold 6,551 common shares in open-market transactions at prices around $90.00 to $90.10 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 61,202 Kymera Therapeutics shares.
Kymera Therapeutics director Bruce Booth reported option exercises and share sales in Kymera Therapeutics, Inc. common stock. Booth exercised stock options to acquire 6,359 shares at an exercise price of $14.18 per share, then sold 6,359 directly held shares in open-market trades around $90 per share.
Additional sales of 2,750 shares and 385 shares were made by investment funds Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with which Booth is associated and where he disclaims Section 16 beneficial ownership except for any pecuniary interest. These transactions, totaling 9,494 shares sold, were executed under Rule 10b5-1 trading plans adopted in December 2025, indicating they were pre-arranged rather than timed discretionarily.
Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options and sold shares in a planned series of transactions. On April 9, he exercised options to acquire 2,500 shares of common stock at an exercise price of $21.05 per share and continued to hold 97,500 options afterward. He then sold a total of 10,264 shares of common stock on April 9 and 10 in open-market transactions at weighted average prices around the mid-$80s to high-$80s. Footnotes state that some shares were sold automatically to cover tax withholding on vested RSUs and that the trades were made under a Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly holds 51,542.438 shares of Kymera common stock.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and related stock sales in Kymera common stock. He exercised stock options covering 22,240 shares at an exercise price of $29.64 per share on March 31 and April 1, 2026, converting derivative positions into common shares.
On the same dates, he sold 22,240 shares of common stock in open-market transactions at weighted average prices between $85.02 and $85.97 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly owns 61,202 shares of Kymera common stock.
Kymera Therapeutics director Elena Ridloff exercised stock options covering 12,000 shares of common stock at an exercise price of $14.18 per share, then sold 12,000 shares in open-market transactions at weighted average prices around $85–$86 under a pre-arranged Rule 10b5-1 trading plan, leaving no directly held common shares reported.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a series of option exercises and share sales in Kymera Therapeutics, Inc. common stock. He exercised stock options to acquire 109,127 shares at an exercise price of $29.64 per share and then sold 115,977 shares of common stock in multiple open-market transactions at weighted average prices ranging from the mid-$70s to about $80 per share, as detailed in the footnotes. Following these transactions, he directly held 61,202 shares of Kymera common stock. The filing states that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Kymera Therapeutics director Pamela Esposito exercised options for 2,500 shares of Common Stock at an exercise price of $49.10 per share and sold all 2,500 shares the same day. The sales were executed in three open-market transactions at weighted average prices of $77.71, $79.24 and $79.94 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan dated September 17, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.
Kymera Therapeutics, Inc. Chief Operating Officer Jeremy G. Chadwick exercised stock options for 20,000 shares of common stock at an exercise price of $43.50 per share. He then sold a total of 25,758 shares of common stock in open-market transactions at weighted average prices of $82.1275, $83.1013, and $83.7195 per share, as part of multiple trades within specified price ranges.
The filing states these transactions were completed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the transactions, Chadwick directly holds 68,052 shares of Kymera Therapeutics common stock.
Kymera Therapeutics reported that Chief Legal Officer Brian Adams received new equity awards. He was granted a stock option for 8,250 shares at an exercise price of $0.00 per share, and 4,125 shares of common stock in the form of restricted stock units. The RSUs vest in four equal annual installments following March 2, 2026, while the stock option vests in 48 equal monthly installments following the same date, in each case contingent on continued employment.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of equity awards and share sales. On March 2, 2026 he received 12,575 restricted stock units that vest in three equal annual installments following March 3, 2025, plus a stock option for 25,150 shares vesting in 48 equal monthly installments following March 2, 2026. That same day he sold 2,039 common shares in open‑market transactions, including shares sold automatically to cover tax withholding on vesting RSUs. On March 4, 2026 he sold an additional 3,919 common shares in open‑market transactions at weighted average prices ranging from $83.9965 to $89.6574 per share. After these transactions he directly owned 73,810 Kymera common shares, in addition to the newly granted option award.
Kymera Therapeutics, Inc. reported that Chief Business Officer Noah Goodman received new equity awards. On March 2, 2026, he was granted a stock option for 18,450 shares at an exercise price of $0.00 per share and 9,225 shares of common stock in the form of restricted stock units. Following the RSU grant, his direct common stock holdings increased to 59,306.438 shares. The RSUs vest in four equal annual installments after March 2, 2026, while the option vests in 48 equal monthly installments after that date, in each case conditioned on continued employment.
Kymera Therapeutics Chief Medical Officer Jared Gollob reported multiple insider transactions. He sold a net 10,508 shares of common stock in several open-market sales on March 2 and March 4, 2026, at weighted average prices in the mid-$80s per share. On March 2, he also received 17,650 restricted stock units that vest in four equal annual installments after March 2, 2026, and a stock option for 35,300 shares vesting in 48 equal monthly installments, all subject to continued employment. Certain March 2 sales were automatically executed to cover tax withholding from RSU vesting and were not at his discretion.
Kymera Therapeutics Chief Financial Officer Bruce N. Jacobs reported a mix of share sales and new equity awards. Across several open-market transactions on March 2 and March 4, 2026, he sold a total of 12,471 shares of common stock at weighted average prices between roughly $83.9965 and $89.6574 per share, leaving him with 232,588 shares held directly.
On March 2, 2026, he also received 17,650 restricted stock units, which vest in four equal annual installments after that date, and a stock option covering 35,300 shares, vesting in 48 equal monthly installments after the same date. Some of the sales were required solely to cover tax withholding obligations tied to RSU vesting and were executed automatically.
Kymera Therapeutics, Inc. Chief Executive Officer Nello Mainolfi reported receiving a grant of stock options for 215,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
According to the disclosure, the options vest in forty-eight equal monthly installments following March 2, 2026, and each portion will vest only if Mainolfi remains employed through the applicable vesting date. All 215,000 stock options are held as direct ownership following this transaction.
Kymera Therapeutics, Inc. director-associated venture funds reported open-market sales of a combined 81,866 shares of common stock at a weighted average price of about $90.13 per share. Atlas Venture Fund X, L.P. sold 71,814 shares and Atlas Venture Opportunity Fund I, L.P. sold 10,052 shares on March 2, 2026.
These trades were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025. Bruce Booth is a member of the general partner entities of these funds and disclaims Section 16 beneficial ownership of the funds’ holdings except to the extent of his pecuniary interest.
Kymera Therapeutics CEO Nello Mainolfi reported a combination of option exercises and share sales on 2026-02-25. He exercised stock options for 30,000 shares at an exercise price of $2.08 per share, converting a derivative award into common stock.
On the same day he sold a total of 30,000 shares of common stock in open-market transactions at weighted average prices within disclosed ranges between $89.16 and $93.15 per share, pursuant to a pre-established Rule 10b5-1 trading plan dated September 6, 2024. After these transactions, he directly owned 666,195 shares of Kymera common stock.